Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 11/20 | 0.47 |
| ▸ | RAF1 | P04049 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025625 | 0.86 | DDR2 (0.52) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL621164 | 0.86 | KDR (0.51) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL4252282 | 0.83 | KDR (0.55) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL6014786 | 0.83 | KDR (0.53) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL618015 | 0.83 | KDR (0.59) | KDRBRAFRAF1EPHX2CSF1R | |
| SCHEMBL12355381 | 0.83 | KDR (0.59) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL940461 | 0.83 | KDR (0.62) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL12355380 | 0.82 | KDR (0.50) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL12355376 | 0.82 | KDR (0.50) | KDRDDR2BRAFRAF1EPHX2 | |
| SCHEMBL12355383 | 0.82 | KDR (0.50) | KDRBRAFRAF1EPHX2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885DDR2 4100/4885BRAF 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.